Q3 FY2026 · ended Sep 30, 2026 · Revenue $9.16M, -69.2% YoY · Filed Nov 5, 2026
REGENXBIO Inc. (RGNX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $9.2 million and a net loss of $40.7 million. Free cash flow was $38.4 million. As of Sep 30, 2026 it held $251.0 million in cash and investments and $66.5 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGNX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Rockville, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1590877
- Former names
- ReGenX Biosciences, LLC (until Nov 7, 2013)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $9.2M | $108.0M | $6.4M | $30.3M | $29.7M |
| Operating income | -$35.5M | $29.3M | -$83.4M | -$57.6M | -$52.4M |
| Net income | -$40.7M | $22.7M | -$90.1M | -$67.1M | -$61.9M |
| Diluted EPS | -$0.62 | $0.43 | -$1.72 | -$1.30 | -$1.20 |
| Operating cash flow | $38.6M | -$62.2M | -$76.2M | -$52.3M | -$56.0M |
| Free cash flow | $38.4M | -$63.0M | -$77.4M | -$52.8M | -$56.5M |
| Total assets | $466.0M | $386.6M | $341.9M | $453.0M | $525.2M |
| Total liabilities | $318.0M | $314.9M | $320.8M | $350.3M | $363.8M |
| Stockholders' equity | $148.0M | $71.8M | $21.1M | $102.7M | $161.5M |
| Cash and investments | $251.0M | $105.5M | $150.5M | $240.9M | $302.0M |
| Total debt | $66.5M | $69.0M | $71.1M | $73.5M | $76.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 24, 2026 | Aug 24, 2026 |
All 805 REGENXBIO Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.